Market Overview

Gene Therapy for Ovarian Cancer - 2018-2022 Pipeline Analysis Report - Research and Markets


The "Gene
Therapy for Ovarian Cancer - A Pipeline Analysis Report"
has been added to's offering.

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report, has been
prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the market landscape and its growth prospects
over the coming years. The report also includes a discussion of the key
vendors operating in this market.

The ovarian cancer immunotherapies market has already got some
commercially successful chemotherapy products. However, chemotherapy
often involves a combination of two or more drugs, given intravenously
every 3-4 weeks, and mostly associated with long-lasting side/adverse
effects. Various studies have shown that chemotherapy can damage the
blood-producing cells of the bone marrow, resulting in blood-related

Gene therapy is emerging as one of the most exciting approaches for the
treatment of ovarian cancer. Replacement gene therapy, which replaces
faulty genes with normal ones in the body, is particularly promising and
currently gaining attention. It has potential to cure ovarian cancer and
can be used as a promising option for long-lasting treatment.

Key vendors

  • Takara Bio
  • VBL
  • Therapeutics
  • Targovax
  • Lokon Pharma
  • SiBiono GeneTech
  • Advantagene

Market trends

  • The adoption of replacement gene therapy

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

For more information about this report visit

View Comments and Join the Discussion!